InvestorsHub Logo
icon url

DewDiligence

08/21/11 6:38 PM

#125428 RE: drbio45 #125426

If a non-substitutable Lovenox knockoff entered the market, MNTA would continue to get a 45% share of NVS’ Lovenox profits, i.e. the same economics as the current arrangement.